Follow
Katherine L Nathanson
Katherine L Nathanson
Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania
Verified email at upenn.edu
Title
Cited by
Cited by
Year
The tuberous sclerosis complex
PB Crino, KL Nathanson, EP Henske
New England Journal of Medicine 355 (13), 1345-1356, 2006
20952006
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
20922010
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
AC Huang, MA Postow, RJ Orlowski, R Mick, B Bengsch, S Manne, W Xu, ...
Nature 545 (7652), 60-65, 2017
15892017
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, ...
Cancer cell 18 (6), 683-695, 2010
15072010
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations.
H Meijers-Heijboer, A Van den Ouweland, J Klijn, M Wasielewski, ...
Nature genetics 31 (1), 2002
14242002
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
SM Shaffer, MC Dunagin, SR Torborg, EA Torre, B Emert, C Krepler, ...
Nature 546 (7658), 431-435, 2017
11902017
Gene-panel sequencing and the prediction of breast-cancer risk
DF Easton, PDP Pharoah, AC Antoniou, M Tischkowitz, SV Tavtigian, ...
New England Journal of Medicine 372 (23), 2243-2257, 2015
10612015
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program
MS Brose, TR Rebbeck, KA Calzone, JE Stopfer, KL Nathanson, ...
Journal of the National Cancer Institute 94 (18), 1365-1372, 2002
9922002
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
N Mavaddat, D Barrowdale, IL Andrulis, SM Domchek, D Eccles, ...
Cancer Epidemiology, Biomarkers & Prevention 21 (1), 134-147, 2012
8082012
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ...
British journal of cancer 95 (5), 581-586, 2006
8032006
Network modeling links breast cancer susceptibility and centrosome dysfunction
MA Pujana, JDJ Han, LM Starita, KN Stevens, M Tewari, JS Ahn, ...
Nature genetics 39 (11), 1338-1349, 2007
7312007
A population-based study of genes previously implicated in breast cancer
C Hu, SN Hart, R Gnanaolivu, H Huang, KY Lee, J Na, C Gao, J Lilyquist, ...
New England Journal of Medicine 384 (5), 440-451, 2021
7112021
Comprehensive molecular characterization of pheochromocytoma and paraganglioma
L Fishbein, I Leshchiner, V Walter, L Danilova, AG Robertson, ...
Cancer cell 31 (2), 181-193, 2017
6992017
PTEN Mutation Spectrum and Genotype-Phenotype Correlations in Bannayan-Riley-Ruvalcaba Syndrome Suggest a Single Entity With Cowden Syndrome
DJ Marsh, JB Kum, KL Lunetta, MJ Bennett, RJ Gorlin, SF Ahmed, ...
Human molecular genetics 8 (8), 1461-1472, 1999
6831999
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
6642013
Breast cancer genetics: what we know and what we need
KN Nathanson, R Wooster, BL Weber
Nature medicine 7 (5), 552-556, 2001
6562001
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen, AC Munko, ...
Cancer research 71 (7), 2750-2760, 2011
6532011
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature
KS Hoek, NC Schlegel, P Brafford, A Sucker, S Ugurel, R Kumar, ...
Pigment cell research 19 (4), 290-302, 2006
6292006
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
AC Huang, RJ Orlowski, X Xu, R Mick, SM George, PK Yan, S Manne, ...
Nature medicine 25 (3), 454-461, 2019
6152019
HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
JD Gordan, P Lal, VR Dondeti, R Letrero, KN Parekh, CE Oquendo, ...
Cancer cell 14 (6), 435-446, 2008
6032008
The system can't perform the operation now. Try again later.
Articles 1–20